Shilpa Medicare Commissions Integrated ADC Manufacturing Facility in Dharwad
Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing facility. Located in Dharwad, the plant enables end-to-end production of complex oncology biologics for global markets.
Dr. Reddy's Launches First Generic Bosulif in US Market for $253.8M Opportunity
Dr. Reddy's Laboratories has launched the first-to-market generic version of Bosulif (Bosutinib Tablets 400mg) in the United States. This strategic oncology launch, executed in collaboration with MSN Laboratories, grants the company 180 days of generic drug exclusivity for this specific dosage strength.
Jeena Sikho Lifecare Starts 100-Bed Ayurvedic Hospital Operations in Mathura
Jeena Sikho Lifecare has officially launched operations at its new Sanskriti Ayurvedic P.G. Medical College & Hospital in Mathura, Uttar Pradesh. This 100-bed facility is part of the company's broader strategy to expand its Ayurvedic healthcare infrastructure across India.
Wanbury Ltd Submits DMFs for Global API Launch; Patalganga Unit Receives Zero Observations
Wanbury Limited has initiated expanded regulatory submissions for the global launch of new Active Pharmaceutical Ingredients (APIs). The company filed Drug Master Files for Diphenhydramine HCl and Paroxetine HCl across several international markets while its Patalganga manufacturing facility successfully cleared a Korea MFDS audit.
Anlon Healthcare Targets ₹800 Cr Revenue by FY28 Following 43% Growth in FY26
Anlon Healthcare Limited reported a robust 42.98% year-on-year increase in FY26 revenue, reaching ₹172.22 Crore. The company has announced an aggressive expansion plan targeting up to ₹800 Crore in revenue by FY28, supported by ₹130 Crore in planned capital expenditure.
Gujarat Themis Biosyn Board Approves ₹1,000 Crore Fund Raise via QIP and Preferential Issue
The Board of Directors of Gujarat Themis Biosyn has authorized a significant capital raise of up to ₹1,000 crore through Qualified Institutions Placement. In addition to the QIP, the company will initiate a preferential issue of equity shares to non-promoter investors to bolster its financial position.
Glenmark Pharmaceuticals Launches Lacosamide Injection in USA Targeting $15.2M Market
Glenmark Pharmaceuticals Inc., USA, has announced the commercial launch of Lacosamide Injection USP, a generic version of Vimpat®. This move expands the company's injectable portfolio in the United States, targeting a market with approximately $15.2 million in annual sales as of April 2026.
Alkem Laboratories Launches India's First Semaglutide Pre-Filled Syringes at ₹350
Alkem Laboratories has launched India's first semaglutide single-shot pre-filled syringes at a disruptive starting price of INR 350. This strategic expansion follows the company's March 2026 launch of injection pens and aims to lower entry barriers for patients managing Type 2 diabetes and obesity.
Amanta Healthcare Commissions 10.8 MWp Solar Plant to Reduce Operational Costs
Amanta Healthcare has successfully commissioned a new 10.8 MWp solar power plant in Gujarat to meet its internal energy requirements. The facility became operational on May 30, 2026, marking a significant step toward energy self-sufficiency and operational cost reduction.